Li Bai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Li Bai has a total of 197 co-authors. Here are the top co-authors by number of shared publications:
- Chengying Li
Department of Epidemiology, College of Preventive Medicine, Army Medical University (Third Military Medical University), Chongqing, People’s Republic of China
11 shared publications - Huimin Zhang
State Key Laboratory of Immune Response and Immunotherapy, Department of Health Management Center of the First Affiliated Hospital, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
11 shared publications - Meiyu Zhou
Department of Epidemiology, College of Preventive Medicine, Army Medical University (Third Military Medical University), Chongqing, People’s Republic of China
11 shared publications - Menglei Chen
Department of Epidemiology, College of Preventive Medicine, Army Medical University (Third Military Medical University), Chongqing, People’s Republic of China
11 shared publications - Na Wu
Department of Epidemiology, College of Preventive Medicine, Army Medical University (Third Military Medical University), Chongqing, People’s Republic of China
11 shared publications - Tingting Xia
Department of Epidemiology, College of Preventive Medicine, Army Medical University (Third Military Medical University), Chongqing, People’s Republic of China
11 shared publications
Latest Publications
- 30 April 2026
- Published by Springer Nature in Science China Life Sciences
- Vol. 69 (9) , 1-11
Human MAITregs possess diverse TCR repertoires and are functionally supported by glycolysis
Mucosal-associated invariant T (MAIT) regulatory cells (MAITregs) represent a specialized subset with immunosuppressive functions, yet their properties and molecular basis are largely unknown. We demonstrate that MAITregs, while sharing T cell receptor (TCR) repertoires with conventional MAIT cells, undergo selective clonal expansion during in vitro generation, leading to biased V(D)J profiles and restricted CDR3 diversity. Moreover, integrated transcriptomics revealed that MAITregs preferred glycolysis, which was supported by chromatin remodeling at glycolytic gene loci. Functionally, glycolysis in MAITregs favored their IL-10 production but inhibited Th1 cytokines, whereas oxidative phosphorylation (OXPHOS) promoted their Th1/Th17 cytokines. Our study defines MAITregs as a clonally expanded population whose regulatory potency is strictly governed by cellular metabolism.
- 30 April 2026
- Published by Springer Nature in Science China Life Sciences
- Vol. 69 (9) , 1-11
Human MAITregs possess diverse TCR repertoires and are functionally supported by glycolysis
Mucosal-associated invariant T (MAIT) regulatory cells (MAITregs) represent a specialized subset with immunosuppressive functions, yet their properties and molecular basis are largely unknown. We demonstrate that MAITregs, while sharing T cell receptor (TCR) repertoires with conventional MAIT cells, undergo selective clonal expansion during in vitro generation, leading to biased V(D)J profiles and restricted CDR3 diversity. Moreover, integrated transcriptomics revealed that MAITregs preferred glycolysis, which was supported by chromatin remodeling at glycolytic gene loci. Functionally, glycolysis in MAITregs favored their IL-10 production but inhibited Th1 cytokines, whereas oxidative phosphorylation (OXPHOS) promoted their Th1/Th17 cytokines. Our study defines MAITregs as a clonally expanded population whose regulatory potency is strictly governed by cellular metabolism.
- 17 April 2026
- Published by Springer Nature in Science China Life Sciences
- Vol. 69 (7) , 2328-2341
Artemisinin derivative SM934 targets α-enolase to inhibit PEP-mediated TAK1 stabilization and inflammation
TGF-β-activated kinase 1 (TAK1) is a key signaling hub and drug target in inflammatory responses. Although metabolism has been critically linked to immune cell function and inflammation, the metabolic control of TAK1 activation and intervention strategy remains to be explored. Here, we show that SM934, a derivative of the traditional Chinese medicine artemisinin, inhibits inflammatory responses via targeting α-enolase and inhibiting metabolite phosphoenolpyruvate (PEP) production. PEP directly binds TAK1 and inhibits its ubiquitination at the lysine-72 site, which promotes NF-κB activation and inflammatory responses. Overall, our study demonstrates a metabolic control of TAK1 stabilization and proposes that it could be disrupted by the derivative of the natural product artemisinin.
- 17 April 2026
- Published by Springer Nature in Science China Life Sciences
- Vol. 69 (7) , 2328-2341
Artemisinin derivative SM934 targets α-enolase to inhibit PEP-mediated TAK1 stabilization and inflammation
TGF-β-activated kinase 1 (TAK1) is a key signaling hub and drug target in inflammatory responses. Although metabolism has been critically linked to immune cell function and inflammation, the metabolic control of TAK1 activation and intervention strategy remains to be explored. Here, we show that SM934, a derivative of the traditional Chinese medicine artemisinin, inhibits inflammatory responses via targeting α-enolase and inhibiting metabolite phosphoenolpyruvate (PEP) production. PEP directly binds TAK1 and inhibits its ubiquitination at the lysine-72 site, which promotes NF-κB activation and inflammatory responses. Overall, our study demonstrates a metabolic control of TAK1 stabilization and proposes that it could be disrupted by the derivative of the natural product artemisinin.
- 14 April 2026
- Published by Springer Nature in Cellular & Molecular Immunology
- p. 1-14
MAIT cell plasticity generates CD4+ MAIT cells that promote HCC progression via metabolic crosstalk with tumor cells
Mucosal-associated invariant T cells (MAITs) are enriched in the liver and closely related to human hepatocellular carcinoma (HCC), but their role is controversial. Whether and how the plasticity of MAITs modulates HCC progression remain to be explored. Here, we revealed that CD4+ MAITs displaying Th17 features were the major source of IL-17A in human HCC. IL-17A from Th17-polarized CD4+ MAITs promoted HCC progression by enhancing lipid storage and tumor cell proliferation in a PPARα dependent manner. Additionally, we showed that both TCR-dependent and TCR-independent activation signaling induced Th17-polarized CD4+ MAIT differentiation and that strong signaling promoted their differentiation. Moreover, IL-17A production in CD4+ MAITs was promoted by glycolysis via posttranscriptional regulation, and tumor cell-derived kynurenine enhanced glycolysis and IL-17A production through the AHR pathway. These findings demonstrate that the plasticity of MAITs and the generation of CD4+ MAITs promote HCC progression via metabolic crosstalk with tumor cells.
- 14 April 2026
- Published by Springer Nature in Cellular & Molecular Immunology
- p. 1-14
MAIT cell plasticity generates CD4+ MAIT cells that promote HCC progression via metabolic crosstalk with tumor cells
Mucosal-associated invariant T cells (MAITs) are enriched in the liver and closely related to human hepatocellular carcinoma (HCC), but their role is controversial. Whether and how the plasticity of MAITs modulates HCC progression remain to be explored. Here, we revealed that CD4+ MAITs displaying Th17 features were the major source of IL-17A in human HCC. IL-17A from Th17-polarized CD4+ MAITs promoted HCC progression by enhancing lipid storage and tumor cell proliferation in a PPARα dependent manner. Additionally, we showed that both TCR-dependent and TCR-independent activation signaling induced Th17-polarized CD4+ MAIT differentiation and that strong signaling promoted their differentiation. Moreover, IL-17A production in CD4+ MAITs was promoted by glycolysis via posttranscriptional regulation, and tumor cell-derived kynurenine enhanced glycolysis and IL-17A production through the AHR pathway. These findings demonstrate that the plasticity of MAITs and the generation of CD4+ MAITs promote HCC progression via metabolic crosstalk with tumor cells.
- Open Access
- 31 January 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Microbiota-induced EI24 improves homeostasis but impedes function of alveolar macrophages via metabolic regulation
Lung microenvironment controls the homeostasis and function of alveolar macrophages (AMs), the major regulators of lung immunity, but the underlying mechanisms, particularly the role of microbiota, remain unclear. Here, with Lyz2creEi24fl/fl mice, we report that EI24 deficiency in macrophages disrupts AMs homeostasis but enhances their phagocytosis and inflammatory responses via metabolic rewiring. Consequently, Lyz2creEi24fl/fl mice exhibit resistance to viral infection and tumor metastasis in lung. Notably, EI24 expression in AMs is upregulated by commensal microbiota through TLR2/4 signaling. These data demonstrate that microbiota upregulates EI24 in AMs to favor their homeostasis, but it retards their immune surveillance function in the lung. Our study thus indicates that deleting EI24 enhances anti-viral and anti-tumor effects of macrophage-based immunotherapy.
- 31 January 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessMicrobiota-induced EI24 improves homeostasis but impedes function of alveolar macrophages via metabolic regulation
Lung microenvironment controls the homeostasis and function of alveolar macrophages (AMs), the major regulators of lung immunity, but the underlying mechanisms, particularly the role of microbiota, remain unclear. Here, with Lyz2creEi24fl/fl mice, we report that EI24 deficiency in macrophages disrupts AMs homeostasis but enhances their phagocytosis and inflammatory responses via metabolic rewiring. Consequently, Lyz2creEi24fl/fl mice exhibit resistance to viral infection and tumor metastasis in lung. Notably, EI24 expression in AMs is upregulated by commensal microbiota through TLR2/4 signaling. These data demonstrate that microbiota upregulates EI24 in AMs to favor their homeostasis, but it retards their immune surveillance function in the lung. Our study thus indicates that deleting EI24 enhances anti-viral and anti-tumor effects of macrophage-based immunotherapy.
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from m6A-Modified SFTA1P Acts as a Tumor Suppressor in Non–Small Cell Lung Cancer by Regulating TGFBR2 and P-TEFb
Primers and RNA oligonucleotides sequences used in this study.
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from m6A-Modified SFTA1P Acts as a Tumor Suppressor in Non–Small Cell Lung Cancer by Regulating TGFBR2 and P-TEFb
Primers and RNA oligonucleotides sequences used in this study.
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from m6A-Modified SFTA1P Acts as a Tumor Suppressor in Non–Small Cell Lung Cancer by Regulating TGFBR2 and P-TEFb
The expression of YTHDC1 level in shNC and shYTHDC1 in A549 and H1299 cells, detected by qRT-PCR and western blotting.
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from m6A-Modified SFTA1P Acts as a Tumor Suppressor in Non–Small Cell Lung Cancer by Regulating TGFBR2 and P-TEFb
The expression of YTHDC1 level in shNC and shYTHDC1 in A549 and H1299 cells, detected by qRT-PCR and western blotting.
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from m6A-Modified SFTA1P Acts as a Tumor Suppressor in Non–Small Cell Lung Cancer by Regulating TGFBR2 and P-TEFb
The gene expression correlations between SFTA1P and downstream target genes of TGF-β signaling pathway.
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from m6A-Modified SFTA1P Acts as a Tumor Suppressor in Non–Small Cell Lung Cancer by Regulating TGFBR2 and P-TEFb
The gene expression correlations between SFTA1P and downstream target genes of TGF-β signaling pathway.
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from m6A-Modified SFTA1P Acts as a Tumor Suppressor in Non–Small Cell Lung Cancer by Regulating TGFBR2 and P-TEFb
The protein expression of E-cadherin and Vimentin were evaluated by WB in H1299 cells after treated with siRNA targeting SFTA1P and BAY-1143572 (1μM).
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from m6A-Modified SFTA1P Acts as a Tumor Suppressor in Non–Small Cell Lung Cancer by Regulating TGFBR2 and P-TEFb
The protein expression of E-cadherin and Vimentin were evaluated by WB in H1299 cells after treated with siRNA targeting SFTA1P and BAY-1143572 (1μM).
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Data from m6A-Modified SFTA1P Acts as a Tumor Suppressor in Non–Small Cell Lung Cancer by Regulating TGFBR2 and P-TEFb
SFTA1P is a pseudogene-derived long noncoding RNA and has become a master regulator in tumor carcinogenesis and progression processes. SFTA1P has been reported as a potential diagnostic and prognostic biomarker in non–small cell lung cancer (NSCLC). The downregulation of SFTA1P in tumor tissue has been associated with poor prognosis; however, the detailed molecular mechanism and biological functions still need to be investigated. We demonstrated that SFTA1P inhibited the growth and metastasis of NSCLC in vitro and in vivo. SFTA1P had dual functions in the cytoplasm and nucleus: In the cytoplasm, SFTA1P can serve as a “sponge” for miR-665 to increase the expression level of TGFBR2; in the nucleus, SFTA1P can bind the positive transcription elongation factor b and subsequently inhibit the transcriptase activity of RNA polymerase II. The regulation of TGFBR2 and positive transcription elongation factor b via SFTA1P depends on its subcellular localization, which was affected by the status of the N6-methyladenosine RNA modification of SFTA1P. Our research demonstrated that the candidate tumor-suppressor SFTA1P is extensively involved in NSCLC, which may offer novel insights into NSCLC oncogenesis.Implications:SFTA1P is downregulated in NSCLC and had dual functions in the cytoplasm and nucleus.
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from m6A-Modified SFTA1P Acts as a Tumor Suppressor in Non–Small Cell Lung Cancer by Regulating TGFBR2 and P-TEFb
SFTA1P is a pseudogene-derived long noncoding RNA and has become a master regulator in tumor carcinogenesis and progression processes. SFTA1P has been reported as a potential diagnostic and prognostic biomarker in non–small cell lung cancer (NSCLC). The downregulation of SFTA1P in tumor tissue has been associated with poor prognosis; however, the detailed molecular mechanism and biological functions still need to be investigated. We demonstrated that SFTA1P inhibited the growth and metastasis of NSCLC in vitro and in vivo. SFTA1P had dual functions in the cytoplasm and nucleus: In the cytoplasm, SFTA1P can serve as a “sponge” for miR-665 to increase the expression level of TGFBR2; in the nucleus, SFTA1P can bind the positive transcription elongation factor b and subsequently inhibit the transcriptase activity of RNA polymerase II. The regulation of TGFBR2 and positive transcription elongation factor b via SFTA1P depends on its subcellular localization, which was affected by the status of the N6-methyladenosine RNA modification of SFTA1P. Our research demonstrated that the candidate tumor-suppressor SFTA1P is extensively involved in NSCLC, which may offer novel insights into NSCLC oncogenesis.Implications:SFTA1P is downregulated in NSCLC and had dual functions in the cytoplasm and nucleus.
- Open Access
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from m6A-Modified SFTA1P Acts as a Tumor Suppressor in Non–Small Cell Lung Cancer by Regulating TGFBR2 and P-TEFb
The expression patterns and subcellular localization of SFTA1P in lung cancer cell lines.
- 4 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from m6A-Modified SFTA1P Acts as a Tumor Suppressor in Non–Small Cell Lung Cancer by Regulating TGFBR2 and P-TEFb
The expression patterns and subcellular localization of SFTA1P in lung cancer cell lines.